Relief For Pradaxa: Praxbind Gets HTA Green Light
This article was originally published in Scrip
Executive Summary
Boehringer Ingelheim's Praxbind (idarucizumab), the antidote to the company's blood thinner Pradaxa (dabigatran), is now reimbursed in England, Wales and Ireland after national health technology appraisal bodies said there was no need to put the drug through a full assessment. The news gives Pradaxa a slight advantage over rival novel anticoagulants, which currently do not yet have antidotes, says Datamonitor Healthcare analyst Jack Allen.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.